"DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination" - Marijuana Moment
Portfolio Pulse from Benzinga Newsdesk
The DEA has clarified that psychedelic mushroom spores are federally legal prior to germination as they do not contain psilocybin or psilocin. This clarification does not change the legal status of the spores, which are illegal in some states and may still be considered drug paraphernalia depending on their marketing or use. The DEA also discussed the legal status of marijuana seeds, delta-8 THC, and synthetic cannabinoids, indicating ongoing regulatory efforts and interpretations.
January 04, 2024 | 4:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
DEA's clarification on psychedelic mushroom spores may indirectly affect CMPS, which is involved in the development of psilocybin therapies, by potentially influencing public perception and regulatory landscape.
While the DEA's letter does not directly impact CMPS's operations, it may influence the broader regulatory and public perception landscape, which can indirectly affect companies in the psychedelics space.
CONFIDENCE 70
IMPORTANCE 40
RELEVANCE 50
NEUTRAL IMPACT
Cybin Inc. (CYBN), which focuses on psychedelic therapeutics, may experience indirect effects from the DEA's clarification, potentially affecting investor sentiment and the regulatory environment.
The DEA's clarification does not have a direct impact on CYBN, but it contributes to shaping the legal and regulatory context in which the company operates, potentially affecting investor sentiment.
CONFIDENCE 70
IMPORTANCE 40
RELEVANCE 50
NEUTRAL IMPACT
Bright Minds Biosciences (DRUG) may see indirect impacts from the DEA's statement on psychedelic spores, which could influence the regulatory environment and investor outlook in the sector.
The DEA's letter does not directly pertain to DRUG, but it may affect the overall regulatory environment and investor outlook for companies involved in psychedelic research.
CONFIDENCE 70
IMPORTANCE 40
RELEVANCE 50
NEUTRAL IMPACT
Enveric Biosciences (ENVB), with its focus on cannabinoid-based medicines, may be indirectly impacted by the DEA's ongoing regulatory discussions, which could affect the legal landscape and investor sentiment.
Although the DEA's letter is not directly related to ENVB's operations, the ongoing regulatory discussions could influence the legal landscape for cannabinoid-based medicines and investor sentiment.
CONFIDENCE 70
IMPORTANCE 40
RELEVANCE 50
NEUTRAL IMPACT
Mind Medicine (MNMD) may be indirectly affected by the DEA's clarification on psychedelic spores, as it could shape the regulatory framework and public perception in the psychedelics industry.
The DEA's statement does not have a direct impact on MNMD, but it may influence the regulatory framework and public perception, which can indirectly affect companies in the psychedelics industry.
CONFIDENCE 70
IMPORTANCE 40
RELEVANCE 50
NEUTRAL IMPACT
Seelos Therapeutics (SEEL), involved in the development of psychiatric and neurological therapeutics, may be indirectly influenced by the DEA's clarification, potentially affecting the regulatory climate and investor sentiment.
The DEA's clarification does not directly impact SEEL, but it may influence the regulatory climate and investor sentiment towards companies developing psychiatric and neurological therapeutics.
CONFIDENCE 70
IMPORTANCE 40
RELEVANCE 50